{"id":7058,"date":"2012-02-28T22:47:57","date_gmt":"2012-02-28T21:47:57","guid":{"rendered":"http:\/\/www.ilmelanoma.com\/?p=7058"},"modified":"2026-10-16T10:47:01","modified_gmt":"2026-10-16T09:47:01","slug":"vemurafenib-doubles-survival-in-braf-v600-mutant-metastatic-melanoma","status":"publish","type":"post","link":"https:\/\/www.ilmelanoma.com\/en\/vemurafenib-doubles-survival-in-braf-v600-mutant-metastatic-melanoma\/","title":{"rendered":"Vemurafenib Doubles Survival in BRAF V600\u2013Mutant Metastatic Melanoma"},"content":{"rendered":"<p>A study published the 23rd February 2012 on \u00a0New England Journal of Medicine (N Engl J Med 2012; 366:707-714),\u00a0shows that Velmurafenib\u00a0(Zelboraf), a drug approved by the U.S. Food and Drug Administration in 2011, double survival of patients affected by advanced melanoma BRAF V600 Mutant. In a large group of patients survival approached 16 months, which is far beyond what we have seen in other trials; 14 percent of patients failed to show any response to Zelboraf.<\/p>\n<p>Read the article: <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1112302\" target=\"_blank\">Survival in BRAF V-600-Mutant Adbvanced Melanoma Treated with Vemurafenib<\/a><\/p>\n<p><a href=\"https:\/\/www.ilmelanoma.com\/en\/vemurafenib-2\/\" target=\"_blank\">Read more about Vemurafenib<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A study published the 23rd February 2012 on \u00a0New England Journal of Medicine (N Engl J Med 2012; 366:707-714),\u00a0shows that Velmurafenib\u00a0(Zelboraf), a drug approved by the U.S. Food and Drug Administration in 2011, double survival of patients affected by advanced melanoma BRAF V600 Mutant. In a large group of patients survival approached 16 months, which [&hellip;]<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-7058","post","type-post","status-publish","format-standard","hentry","category-cura-melanoma"],"_links":{"self":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/7058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/comments?post=7058"}],"version-history":[{"count":1,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/7058\/revisions"}],"predecessor-version":[{"id":10808,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/7058\/revisions\/10808"}],"wp:attachment":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/media?parent=7058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/categories?post=7058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/tags?post=7058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}